The Online Investor



89bio Inc (ETNB)

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.

ETNB SEC Filing Email Alerts Service
Company Name: 
89bio Inc
Website: 
www.89bio.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ETNB: 
24
Total Market Value Held by ETFs: 
$127.21M
Total Market Capitalization: 
$1.05B
% of Market Cap. Held by ETFs: 
12.15%
Quotes delayed 20 minutes

Email EnvelopeFree ETNB Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.60 out of 4)
63rd percentile
(ranked higher than approx. 63% of all stocks covered)

Analysts' Target Price:
ETNB Stock Forecast

Based on Zacks ABR data;
powered by Xignite

89bio Inc (ETNB) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.